Neoadjuvant chemotherapy for unresectable ovarian carcinoma

Abstract

Wood is a hierarchical composite, consisting at its lowest hierarchy level of crystalline cellulose elementary fibrils with diameters of 2–4 nm embedded in a matrix of hemicelluloses and lignin. At the micrometer scale, it has a cellular architecture resembling a honeycomb structure. The transformation of the hierarchical wood structure into a silica replica has been reported recently. Its formation process and structural details are studied in this contribution. First, a silica/biopolymer composite is prepared by wood delignification and cell‐wall modification, followed by silica precursor infiltration and condensation. The calcination process is monitored to gain insight into the structure development upon decomposition of the biopolymers. The material changes its architecture gradually from fibrillar structures of 10–20 nm in diameter with homogeneous electron density, into fibrils of 8–10 nm in diameter with inhomogeneous electron density, exhibiting internal sub‐fibrillar structures of about 2 nm in diameter. The steps of the successful replication of the cellulose elementary fibrils into nanopores of similar diameter and orientation in a fibrillar silica matrix are demonstrated. These nanopore replicas of the original cellulose are wound in a steep helix within the macropore walls. These advanced materials may have lightweight structural applications and the nanopores may be advantageous for molecular separation.

Feasibility evaluation for selection of neoadjuvant chemotherapy before cytoreduction of advanced ovarian carcinoma

“…Multiple studies have shown that neoadjuvant chemotherapy can improve the surgical condition for AOC patients that fail to receive a surgical operation, with enhancement of surgical optimality, reduction of postoperative recurrence and improvement of prognosis etc. [2,3] Neoadjuvant chemotherapy, combined with cytoreduction, has become a selectable regimen for AOC treatment. In this article we have reviewed advances in the preoperative evaluation of AOC cytoreduction.…”

Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer

“…Multiple studies suggested that patients of advanced ovarian cancer treated with NAC improved performance status, decreased the extent and morbidity of surgery, and increased the opportunity of optimal debulking surgery [2,[4][5][6][7][8][10][11][12]. Therefore, it is natural to consider NAC followed by IDS to be an alternative to conventional PDS in treating advanced ovarian cancer and expect that the NAC group would have better survival than PDS group.…”

Low-grade serous ovarian cancer: a unique disease

“…The 4% response rate noted in this study was significantly lower than the previously reported response rates of 60% to 80% for neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma [33,34]. These fi ndings suggest that low-grade serous carcinomas of the ovary and peritoneum are not as responsive as high-grade serous carcinomas are to conventional chemotherapy with platinum and taxane agents.…”